Nonalcoholic Steatohepatitis Treatment Market Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Nonalcoholic Steatohepatitis Treatment Market
Nonalcoholic steatohepatitis
(NASH) is a non-alcoholic liver disease that causes liver damage. It is
particularly common in patients who have at least one risk factor, such as
dyslipidemia, obesity, or glucose intolerance. NASH pathophysiology is not
fully understood, but it is thought to be associated to insulin resistance. It
is diagnosed by blood testing, imaging studies, and, in certain cases, a liver
biopsy. NASH treatment comprises removing the causes and risk factors, such as
lowering the body's fat content.
The rising incidence of
nonalcoholic steatohepatitis, combined with a robust product pipeline, is
likely to fuel growth in the nonalcoholic
steatohepatitis treatment market throughout the forecast period.
Nonalcoholic steatohepatitis has become one of the most frequent liver
diseases. The illness has been connected to a poor diet and weight increase,
but it can also be seen in non-obese people. The majority of therapies for
Nonalcoholic Steatohepatitis Treatment are in early or mid-stage development,
with some in late-stage research. Several businesses are working to develop
medications for fatty liver.
For example, AstraZeneca licenced
IONIS-AZ6-2.5-L, which was renamed AZD2693 in April 2018. The newly approved
medicine is intended to treat patients with nonalcoholic steatohepatitis by
inhibiting an unidentified target.
Comments
Post a Comment